Teva/Barr Combination Creates Biosimilar Force
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva’s $7.46 billion acquisition of Barr will result in a generics powerhouse, expanding U.S. leadership and geographic footprint.
You may also be interested in...
Mylan’s Biogenerics Strategy: Build Standards From Europe, Be Financially Cautious
Generic firm is counting on Global Biologics Head Patrick Vink’s experience as Sandoz biopharma head to lead the firm into the follow-on biologics marketplace.
Mylan’s Biogenerics Strategy: Build Standards From Europe, Be Financially Cautious
Generic firm is counting on Global Biologics Head Patrick Vink’s experience as Sandoz biopharma head to lead the firm into the follow-on biologics marketplace.
Teva Expects To Launch First Biosimilar In Europe By Year End
During its second-quarter earnings call, Teva says it is taking steps to launch a G-CSF product in Europe.